Alltracel commences co-funded development on PhytopeuticsTM with a major global
leader in the functional cosmetic/cosmeceutical ingredient market
- successful conclusion to this six month joint product development program will
lead to a formal alliance agreement with this global market leader -
7.00am June 12th, 2007: Dublin, Ireland & Prague, Czech Republic
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the
Healthcare Innovation Group focused on the Wound Care, Oral Care, Cardiovascular
Health and Cosmeceutical markets, is today pleased to announce it has begun a
six month co-funded product development programme with a leading global
commercialisation partner in the cosmeceuticals ingredient market. The
successful conclusion of the programme will lead to both parties entering into
an alliance to commercialise the PhytopeuticsTM range of dermal health solutions
in the global cosmeceutical market.
The scope of the co-funded product development programme will focus on
development of the following proven PhytopeuticsTM properties:
- Collagen and Elastin Stimulation - replenishing the skins natural strength
and elasticity to combat the signs of ageing.
- Moisturisation / Skin Hydration - retaining the skins moisture and helping
reduce the signs of skin damage and ageing
- Anti-Oxidation - boosting the skin's defenses against damage
Alltracel's CEO, Tony Richardson, commented:
"PhytopeuticsTM provides a full range of dermal health solutions for all ages of
skin. This co-funded development programme is for six months and involves three
distinct phases. The successful outcome will lead to a formal alliance between
Alltracel and our partner who is a global leader in the functional skin care
ingredient market with specific expertise in the final formulation of complex
skin care products. We are very excited about working closely with this global
leader whose experience and reputation in this market further strengthens the
PhytopeuticsTM offering and brings Alltracel a step closer to entering the high
consumption, high margin international cosmeceutical marketplace."
Ends
For Further Information Contact:
Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com
London: Deborah Scott Financial Dynamics: +44 207 831 3113
Notes to Editors:
PhytopeuticsTM (www.phytopeutics.com) is a range of dermal health solutions
derived from Alltracel's patented technology and targeting the functional
cosmetic/cosmeceuticals market.
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.
Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovative technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (www.westoneproducts.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of NanospiderTM technology for the global
healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas such as Wound Care, Cardiovascular Health and Skin
Care.
m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc.
NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.
This information is provided by RNS
The company news service from the London Stock Exchange
Alltracel Pharmaceuticals Plc announces Re Agreement
| Source: Alltracel Pharmaceuticals Plc
DUBLIN, IRELAND--(Marketwire - June 12, 2007) -